The FDA and state and local partners have collected multiple samples of Diamond Shruumz-brand products for testing and analysis. Sample analysis is ongoing; however, as of August 8, 2024, test results are available for 19 Diamond Shruumz-brand Chocolate Bars. The Diamond Shruumz-brand Cones and Gummies samples have also been collected, and testing and analysis are ongoing. To date, the FDA has tested 19 samples of Chocolate Bars and one raw ingredient that was reportedly used in the manufacturing of some Diamond Shruumz-brand products. Six (6) of the 19 Chocolate Bars and the raw ingredient contained muscimol. Muscimol does not appear in all products and cannot explain all the symptoms reported by ill patients who consumed the Diamond Shruumz-brand Chocolate Bars. In addition to muscimol, FDA analyses of Diamond Shruumz-brand Chocolate Bar samples identified the presence of the following compounds: Acetylpsilocin (also known as 4-acetoxy-N, N-dimethyltryptamine, 4-acetoxy-DMT, O-acetylpsilocin or psilacetin) was found in nine (9) Chocolate Bar samples; Psilocin, a Schedule I-controlled substance, was found in four (4) Chocolate Bar samples; Pregabalin, a prescription drug, was found in three (3) Chocolate Bar samples; and Desmethoxyyangonin, dihydrokavain, and kavain (kavalactones found in the kava plant), were all present together in 15 Chocolate Bar samples. As of August 9, 2024, a total of 130 illnesses have been reported from 29 states; 53 have been hospitalized, and there are two potentially associated deaths. @ https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-illnesses-diamond-shruumz-brand-chocolate-bars-cones-gummies-june-2024?utm_medium=email&utm_source=govdelivery
